Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – Here’s Why

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw unusually-strong trading volume on Thursday . Approximately 639,405 shares traded hands during mid-day trading, an increase of 337% from the previous session’s volume of 146,253 shares.The stock last traded at $30.7250 and had previously closed at $30.37.

Analyst Ratings Changes

Separately, UBS Group raised Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, Chugai Pharmaceutical has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Stock Up 1.2%

The firm has a market cap of $101.17 billion, a price-to-earnings ratio of 35.33 and a beta of 0.63. The stock’s 50 day moving average is $27.46 and its 200 day moving average is $24.93.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its earnings results on Thursday, January 29th. The company reported $0.25 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%.The firm had revenue of $2.25 billion during the quarter. Analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.